Systems and methods for predicting vitreous half-life of therapeutic agent-polymer conjugates

A half-life, polymer technology, applied in chemical property prediction, drug delivery, pharmaceutical formulation, etc., can solve problems such as misinterpretation, potential defects of therapeutic agent-polymer conjugates, etc.

Inactive Publication Date: 2018-08-03
GENENTECH INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The immune response to the candidate therapeutic agent in the animal model under consideration demonstrates a misinterpretation of the pharmacokinetic (PK) data obtained during initial testing, and if human or humanized antibodies are used in rabbits as these feasibility in rabbits Investigation of therapeutic agents may lead to flawed conclusions about the potential of therapeutic agent-polymer conjugates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systems and methods for predicting vitreous half-life of therapeutic agent-polymer conjugates
  • Systems and methods for predicting vitreous half-life of therapeutic agent-polymer conjugates
  • Systems and methods for predicting vitreous half-life of therapeutic agent-polymer conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0149] Example 1: Vitreous Pharmacokinetics of rabFab Surrogate Compounds

[0150] Development of delivery technologies for protein therapeutics requires testing in relevant animal models to demonstrate in vivo utility. Rabbit models were commonly used in early studies of ocular pharmacokinetics. Unfortunately, most human and humanized antibodies are immunogenic in rabbits, precluding the use of long-acting delivery technologies to estimate key pharmacokinetic parameters. To address this issue, a rabbit Fab ("rabFab"), a species-matched surrogate compound, was used to evaluate the delivery technology in a rabbit model. The rabFabs described herein are derived from rabbit monoclonal antibodies that bind human phospho-c-Met.

[0151] Methods of making rabbit antibodies, including rabbit monoclonal antibodies, are well known in the art. See, eg, US Patent Nos. 5,675,063 and / or 7,429,487. An exemplary rabbit monoclonal antibody that binds to human phospho-c-Met is commercial...

Embodiment 2

[0166] Example 2: Vitreous Pharmacokinetics of Surrogate-Polymer Conjugates

[0167] To further evaluate the efficacy of rabFab as a surrogate testing technology to improve vitreous pharmacokinetics, a PEGylated version of the rabFab molecule was generated as follows and PK tested using the method described in Example 1. To maintain the binding activity of the rabFab molecule, PEG-maleimide was used for site-specific conjugation to modify the free Cys (Cys-227) in the Fab' form of the rabbit antibody. Linear PEG chains of 20,000 Da and 40,000 Da molecular weight were conjugated to rabFabs to generate PEGylated (20 kD) anti-phospho cMet Fab conjugates and PEGylated (40 kD) anti-phospho cMet Fab conjugates.

[0168] Rabbit Fab' was dialyzed against PBS, pH 7.4, and then EDTA was added to a final concentration of 5 mM. To remove free thiol adducts, fresh DTT was added at a molar ratio of 1:1.2 (Fab':DTT) and samples were left overnight at room temperature. Adduct removal was ...

Embodiment 3

[0178] Example 3: Effect of FcRn Binding on Vitreous Half-Life

[0179] To test the effect of FcRn binding on the kinetics of vitreous clearance, the rabbit model and methods described in Example 1 were used to assess the vitreous half-life of two mutant forms of IgG.

[0180] The effect of binding to the recovered FcRn receptor on the vitreous half-life of IgG was tested with antibody mutations known to abolish FcRn binding. For circulating IgG antibodies, FcRn promotes half-life by protecting IgG from catabolism through non-specific pinocytosis (Roopenian & Akilesh (2007) Nat. Rev. Imm. 7:715). Substitutions H310A and H435Q in the Fc region of the antibody were associated with greatly reduced FcRn binding and rapid systemic clearance (Kenanova et al. (2005) Cancer Res. 65:622). These substitutions were introduced into the Fc portion of the humanized 5B6 (anti-gD) antibody using oligonucleotide-directed mutagenesis as described in Example 4 below. Wild-type and H310A:H435...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
radiusaaaaaaaaaa
Login to view more

Abstract

Disclosed are systems and methods for estimating the vitreous half-life of a therapeutic agent. In particular, systems and methods are disclosed for predicting the vitreous half-life of a therapeuticagent conjugated to a polymer that make use of an empirically-derived relationship of vitreous half-life to the hydrodynamic radius of a candidate therapeutic agent-polymer conjugate. The present disclosure is further directed to the use of the systems and methods disclosed herein to design a candidate therapeutic agent-polymer conjugate with a preselected vitreous half-life.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 238,393, entitled "System and Method for Predicting Vitreous Half-Life of Therapeutic Agent-Polymer Conjugates," filed October 7, 2015, hereby adopted This reference is hereby incorporated in its entirety. technical field [0003] The present application generally relates to systems and methods for predicting the vitreous half-life of therapeutic agent-polymer conjugates. In particular, the present application relates to systems and methods for predicting the vitreous half-life of a therapeutic agent conjugated to a polymer from an empirically derived relationship between the vitreous half-life and the hydrodynamic radius of the therapeutic agent-polymer conjugate. The present application also relates to the use of the systems and methods disclosed herein for designing therapeutic agent-polymer conjugates with a predetermined vitreous half-life. Background techniqu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G06F19/00
CPCG16C20/30A61K9/0048A61K47/60A61K47/61G06F17/18
Inventor R·凯利J·希尔W·沙茨
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap